{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:12:45Z","timestamp":1780585965324,"version":"3.54.1"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,10,4]]},"abstract":"Importance<\/jats:title>Patients with lower extremity peripheral artery disease (PAD) have reduced lower extremity perfusion, impaired lower extremity skeletal muscle function, and poor walking performance. Telmisartan (an angiotensin receptor blocker) has properties that reverse these abnormalities.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether telmisartan improves 6-minute walk distance, compared with placebo, in patients with lower extremity PAD at 6-month follow-up.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Double-blind, randomized clinical trial conducted at 2 US sites and involving 114 participants. Enrollment occurred between December 28, 2015, and November 9, 2021. Final follow-up occurred on May 6, 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>The trial randomized patients using a 2\u2009\u00d7\u20092 factorial design to compare the effects of telmisartan plus supervised exercise vs telmisartan alone and supervised exercise alone and to compare telmisartan alone vs placebo. Participants with PAD were randomized to 1 of 4 groups: telmisartan plus exercise (n\u2009=\u200930), telmisartan plus attention control (n\u2009=\u200929), placebo plus exercise (n\u2009=\u200928), or placebo plus attention control (n\u2009=\u200927) for 6 months. The originally planned sample size was 240 participants. Due to slower than anticipated enrollment, the primary comparison was changed to the 2 combined telmisartan groups vs the 2 combined placebo groups and the target sample size was changed to 112 participants.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the 6-month change in 6-minute walk distance (minimum clinically important difference, 8-20 m). The secondary outcomes were maximal treadmill walking distance; Walking Impairment Questionnaire scores for distance, speed, and stair climbing; and the 36-Item Short-Form Health Survey physical functioning score. The results were adjusted for study site, baseline 6-minute walk distance, randomization to exercise vs attention control, sex, and history of heart failure at baseline.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 114 randomized patients (mean age, 67.3 [SD, 9.9] years; 46 were women [40.4%]; and 81 were Black individuals [71.1%]), 105 (92%) completed 6-month follow-up. At 6-month follow-up, telmisartan did not significantly improve 6-minute walk distance (from a mean of 341.6 m to 343.0 m; within-group change: 1.32 m) compared with placebo (from a mean of 352.3 m to 364.8 m; within-group change: 12.5 m) and the adjusted between-group difference was \u221216.8 m (95% CI, \u221235.9 m to 2.2 m; P<\/jats:italic>\u2009=\u2009.08). Compared with placebo, telmisartan did not significantly improve any of the 5 secondary outcomes. The most common serious adverse event was hospitalization for PAD (ie, lower extremity revascularization, amputation, or gangrene). Three participants (5.1%) in the telmisartan group and 2 participants (3.6%) in the placebo group were hospitalized for PAD.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Among patients with PAD, telmisartan did not improve 6-minute walk distance at 6-month follow-up compared with placebo. These results do not support telmisartan for improving walking performance in patients with PAD.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02593110<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2022.16797","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:05:34Z","timestamp":1664895934000},"page":"1315","source":"Crossref","is-referenced-by-count":18,"title":["Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease"],"prefix":"10.1001","volume":"328","author":[{"given":"Mary M.","family":"McDermott","sequence":"first","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Bazzano","sequence":"additional","affiliation":[{"name":"Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A.","family":"Peterson","sequence":"additional","affiliation":[{"name":"University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sufit","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ferrucci","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute on Aging, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Domanchuk","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar S.","family":"Polonsky","sequence":"additional","affiliation":[{"name":"Pritzker School of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lloyd-Jones","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan","family":"Leeuwenburgh","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack M.","family":"Guralnik","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Maryland, College Park"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina R.","family":"Kibbe","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Virginia, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Kosmac","sequence":"additional","affiliation":[{"name":"University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Criqui","sequence":"additional","affiliation":[{"name":"University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Health Research and Policy, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"21","key":"joi220100r1","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1001\/jama.2021.2126","article-title":"Lower extremity peripheral artery disease without chronic limb-threatening ischemia.","volume":"325","author":"Polonsky","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"joi220100r2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.015929","article-title":"Correlations of calf muscle macrophage content with muscle properties and walking performance in peripheral artery disease.","volume":"9","author":"Kosmac","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"joi220100r3","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/ATVBAHA.120.313831","article-title":"Skeletal muscle pathology in peripheral artery disease.","volume":"40","author":"McDermott","year":"2020","journal-title":"Arterioscl Thrombo Vascular Biol"},{"issue":"7","key":"joi220100r4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1001\/jama.2016.20673","article-title":"Improving lower extremity functioning in peripheral artery disease: exercise, endovascular revascularization, or both?","volume":"317","author":"McDermott","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"joi220100r5","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1177\/0363546508315470","article-title":"Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle.","volume":"36","author":"Bedair","year":"2008","journal-title":"Am J Sports Med"},{"issue":"4 pt 2","key":"joi220100r6","first-page":"H1395","article-title":"Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle.","volume":"275","author":"Nora","year":"1998","journal-title":"Am J Physiol"},{"issue":"2","key":"joi220100r7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/HYPERTENSIONAHA.109.145409","article-title":"Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.","volume":"55","author":"Chai","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"joi220100r8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bbrc.2010.11.139","article-title":"Unique \u201cdelta lock\u201d structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.","volume":"404","author":"Ohno","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"joi220100r9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00392-010-0184-0","article-title":"Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease.","volume":"99","author":"Zankl","year":"2010","journal-title":"Clin Res Cardiol"},{"issue":"24","key":"joi220100r10","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","article-title":"Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association.","volume":"126","author":"Aboyans","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"joi220100r11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1078-5884(97)80102-5","article-title":"A comparative study of treadmill tests and heel raising exercise for peripheral arterial disease.","volume":"13","author":"Amirhamzeh","year":"1997","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"2","key":"joi220100r12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jama.2020.6463","article-title":"Use of run-in periods in randomized trials.","volume":"324","author":"Huo","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"joi220100r13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1067\/mva.2000.108640","article-title":"Lower ankle\/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease.","volume":"32","author":"McDermott","year":"2000","journal-title":"J Vasc Surg"},{"issue":"2","key":"joi220100r14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2008.962","article-title":"Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication.","volume":"301","author":"McDermott","year":"2009","journal-title":"JAMA"},{"issue":"21","key":"joi220100r15","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1001\/jama.2017.17437","article-title":"Effect of granulocyte-macrophage colony stimulating factor with or without supervised exercise on walking performance in patients with peripheral artery disease.","volume":"318","author":"McDermott","year":"2017","journal-title":"JAMA"},{"issue":"13","key":"joi220100r16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2021.2536","article-title":"Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease.","volume":"325","author":"McDermott","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"joi220100r17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.114.007002","article-title":"Six-minute walk is a better outcome measure than treadmill walking tests in therapeutic trials of patients with peripheral artery disease.","volume":"130","author":"McDermott","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"joi220100r18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1249\/00005768-199104000-00003","article-title":"Progressive vs single-stage treadmill tests for evaluation of claudication.","volume":"23","author":"Gardner","year":"1991","journal-title":"Med Sci Sports Exerc"},{"key":"joi220100r19","first-page":"142","article-title":"Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease.","volume":"2","author":"Regensteiner","year":"1990","journal-title":"J Vasc Med Biol"},{"issue":"9","key":"joi220100r21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199503023320902","article-title":"Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability.","volume":"332","author":"Guralnik","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"joi220100r22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jvs.2020.03.052","article-title":"Meaningful change in 6-minute walk in people with peripheral artery disease.","volume":"73","author":"McDermott","year":"2021","journal-title":"J Vasc Surg"},{"issue":"4","key":"joi220100r23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/1358863X18762599","article-title":"Minimal clinically important differences in treadmill, 6-minute walk, and patient-based outcomes following supervised and home-based exercise in peripheral artery disease.","volume":"23","author":"Gardner","year":"2018","journal-title":"Vasc Med"},{"issue":"12","key":"joi220100r24","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/acr.v66.12","article-title":"Clinically important changes in Short Form 36 Health Survey scales for use in rheumatoid arthritis clinical trials.","volume":"66","author":"Ward","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"joi220100r25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jacc.2007.05.030","article-title":"Baseline functional performance predicts the rate of mobility loss in persons with peripheral arterial disease.","volume":"50","author":"McDermott","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"joi220100r26","first-page":"e686","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease.","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"issue":"7","key":"joi220100r27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1111\/jcmm.2011.15.issue-7","article-title":"Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-d\/AMPK pathway.","volume":"15","author":"Feng","year":"2011","journal-title":"J Cell Mol Med"},{"issue":"3","key":"joi220100r28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2337\/db12-0570","article-title":"Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-d activation.","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"joi220100r29","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/bjs.9198","article-title":"Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.","volume":"100","author":"Shahin","year":"2013","journal-title":"Br J Surg"},{"key":"joi220100r30","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jvs.2019.05.058","article-title":"Comparing 6-minute walk versus treadmill walking distance as outcomes in randomized trials of peripheral artery disease.","volume":"71","author":"McDermott","year":"2020","journal-title":"J Vasc Surg"},{"key":"joi220100r20","volume-title":"SF-36 Health Survey: Manual and Interpretation Guide","author":"Ware","year":"1993"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2796948\/jama_mcdermott_2022_oi_220100_1664214338.82844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:05:42Z","timestamp":1664895942000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2796948"}},"subtitle":["The TELEX Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,10,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.16797","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}